Nazneen Rahman | |
---|---|
Nationality | British |
Alma mater | |
Scientific career | |
Thesis | Localisation and characterisation of the familial tumour gene, FWT1 (1999) |
Doctoral advisor | Michael Stratton [1] |
Website | icr |
Sabera Nazneen Rahman CBE FMedSci [2] is a geneticist who specialises in cancer research [3] and is a non-executive director for AstraZeneca. She was previously head of Genetics and Epidemiology at the Institute of Cancer Research. [4] [5]
Rahman qualified in medicine from University of Oxford in 1991, and completed a PhD in Molecular Genetics in 1999 on the Wilms' tumor susceptibility gene FWT1. [6] [7] She completed her Certificate of Completion of Specialist Training in Clinical Genetics in 2001.
She was head of Genetics and Epidemiology at the Institute of Cancer Research, based at the Sir Richard Doll Building in Sutton. She specialises in research into the genetic mechanisms that cause cancer, particularly among groups with a predisposition to pediatric cancers or breast cancer. [8] Through her research, Professor Rahman has provided improved screening and treatment options for NHS patients, and also provides advice on rare cancer genetics to clinicians internationally. [9] She blogs about her work at Harvesting the Genome. [10]
Rahman held a clinical role as head of the cancer genetics service at The Royal Marsden and St George's Hospital in south west London. [1]
Rahman resigned from her position following in October 2018 following upholding on independent investigation of a complaint of systematic bullying spanning 15 years from 44 of her current and former staff and students . [11] Rahman also lost a £3.5-million grant from the Wellcome Trust. [12]
In 2017 Rahman was appointed Non-Executive Director and member of the Science Committee at AstraZeneca Plc. [13]
Rahman was elected a Fellow of the Academy of Medical Sciences in 2010. Her nomination reads: [2]
Nazneen Rahman is Professor of Human Genetics at the Institute of Cancer Research and Head of the Clinical Genetics Department at the Royal Marsden Hospital. Her research work has been directed towards the mapping, identification and clinical characterisation of human disease genes using genome-wide linkage analysis, positional cloning, candidate gene resequencing, genome-wide association analyses and epigenetic assays. Her primary areas of research are breast cancer susceptibility, childhood cancer susceptibility and human growth disorders. In her relatively short career to date she has already identified and characterised 4 breast cancer predisposition genes and two childhood cancer predisposition genes and two overgrowth genes.
In April 2014, she was named as Britain's third most influential woman in the BBC Woman's Hour power list 2014. [14] In February 2016, she was awarded the Services to Science & Engineering award at the British Muslim Awards. [15]
She was appointed Commander of the Order of the British Empire (CBE) in the 2016 Birthday Honours for services to medical science. [16]
Rahman is also a singer-songwriter, with two albums and one EP released. [17]
The Institute of Cancer Research is a public research institute and a member institution of the University of London in London, United Kingdom, specialising in oncology. It was founded in 1909 as a research department of the Royal Marsden Hospital and joined the University of London in 2003. It has been responsible for a number of breakthrough discoveries, including that the basic cause of cancer is damage to DNA.
Mary-Claire King is an American geneticist. She was the first to show that breast cancer can be inherited due to mutations in the gene she called BRCA1. She studies human genetics and is particularly interested in genetic heterogeneity and complex traits. She studies the interaction of genetics and environmental influences and their effects on human conditions such as breast and ovarian cancer, inherited deafness, schizophrenia, HIV, systemic lupus erythematosus and rheumatoid arthritis. She has been the American Cancer Society Professor of the Department of Genome Sciences and of Medical Genetics in the Department of Medicine at the University of Washington since 1995.
Roxana Moslehi is an Iranian-born genetic epidemiologist.
Wilms tumor protein (WT33) is a protein that in humans is encoded by the WT1 gene on chromosome 11p.
BRCA1 associated protein-1 is a deubiquitinating enzyme that in humans is encoded by the BAP1 gene. BAP1 encodes an 80.4 kDa nuclear-localizing protein with a ubiquitin carboxy-terminal hydrolase (UCH) domain that gives BAP1 its deubiquitinase activity. Recent studies have shown that BAP1 and its fruit fly homolog, Calypso, are members of the polycomb-group proteins (PcG) of highly conserved transcriptional repressors required for long-term silencing of genes that regulate cell fate determination, stem cell pluripotency, and other developmental processes.
Partner and localizer of BRCA2, also known as PALB2 or FANCN, is a protein which in humans is encoded by the PALB2 gene.
TOX high mobility group box family member 3, also known as TOX3, is a human gene.
Alan Ashworth, FRS is a British molecular biologist, noted for his work on genes involved in cancer susceptibility. He is currently the President of the UCSF Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, a multidisciplinary research and clinical care organisation that is one of the largest cancer centres in the Western United States. He was previously CEO of the Institute of Cancer Research (ICR) in London.
Sir Michael Rudolf Stratton, is a British clinical scientist and the third director of the Wellcome Trust Sanger Institute. He currently heads the Cancer Genome Project and is a leader of the International Cancer Genome Consortium.
Sir Bruce Anthony John Ponder FMedSci FAACR FRS FRCP is an English geneticist and cancer researcher. He is Emeritus Professor of Oncology at the University of Cambridge and former director of the Cancer Research UK Cambridge Institute and of the Cancer Research UK Cambridge Cancer Centre.
Professor Nicholas Dixon Hastie CBE, FRS, FRSE is a British geneticist, and former Director of the MRC Human Genetics Unit at the University of Edinburgh.
Yusuke Nakamura is a Japanese prominent geneticist and cancer researcher best known for developing Genome-Wide Association Study (GWAS). He is one of the world's pioneers in applying genetic variations and whole genome sequencing, leading the research field of personalized medicine.
Timothy John Phillip Hubbard is a Professor of Bioinformatics at King's College London, Head of Genome Analysis at Genomics England and Honorary Faculty at the Wellcome Trust Sanger Institute in Cambridge, UK. Starting March 1, 2024, Tim will become the director of Europe's Life Science Data Infrastructure ELIXIR.
Wendy K. Chung is an American clinical and molecular geneticist and physician. She is the Chair of the Department of Pediatrics at Boston Children's Hospital and is on the faculty at Harvard Medical School. She is the author of 700 peer-reviewed articles and 75 chapters and has won several awards as a physician, researcher, and professor. Chung helped to initiate a new form of newborn screening for spinal muscular atrophy which is used nationally and was among the plaintiffs in the Supreme Court case which banned gene patenting.
Douglas F. Easton FMedSci is a British epidemiologist who conducts research on the genetics of human cancers. He is Professor of Genetic Epidemiology and Centre for Cancer Genetic Epidemiology at the University of Cambridge. He founded Cambridge's Cancer Research UK Genetic Epidemiology Unit in 1995, and was a Principal Research Fellow there from 2001 to 2011. He is a Professorial Fellow of Homerton College, Cambridge.
Carolyn J. Brown is a Canadian geneticist and Professor in the Department of Medical Genetics at the University of British Columbia. Brown is known for her studies on X-chromosome inactivation, having discovered the human XIST gene in 1990.
Rosalind Anne Eeles is a Professor of Oncogenetics at the Institute of Cancer Research and clinician at the Royal Marsden NHS Foundation Trust. She is a leader in the field of genetic susceptibility to prostate cancer, and is known for the discovery of 14 genetic variants involved in prostate cancer predisposition. According to ResearchGate, Eeles has published more than 500 articles in peer-reviewed journals, with over 34,000 citations and an h-index of 92. Eeles was elected a Fellow of the Academy of Medical Science in 2012. She was awarded a National Institute for Health Research Senior Investigator Emeritus in 2014.
Jórunn Erla Eyfjörð is an Icelandic molecular biologist and professor emerita at the Faculty of Medicine of the University of Iceland. She is known for her research on breast cancer genetics.
Xiaohong Rose Yang is an American biomedical scientist researching the genetics of dysplastic nevus syndrome and chordoma, and etiologic heterogeneity of breast cancer. She is a senior investigator at the National Cancer Institute. Yang leads breast cancer studies in mainland China, Hong Kong, and Malaysia.
Bing Xia is a Chinese American scientist and professor at the Rutgers Cancer Institute of New Jersey, where he directs the Xia Laboratory. He is best known for his discovery of the PALB2 tumor suppressor gene, a notable scientific advance in the field of cancer genetics.
{{cite journal}}
: |first15=
has generic name (help)